MedTrace Logo

Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection

NCT00547235 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2010-08-24

No results posted yet for this study

Summary

RATIONALE: Collecting the T cells from a donor and transplanting them into a patient may be effective treatment for immunodeficiency syndrome and CMV infection.

PURPOSE: This clinical trial is studying the emergency use of adoptive immunotherapy with CMV-specific T cells after donor bone marrow transplant of an infant with immunodeficiency syndrome and CMV infection.

Conditions

  • Infection
  • Precancerous/Nonmalignant Condition

Interventions

BIOLOGICAL

therapeutic allogeneic lymphocytes

PROCEDURE

allogeneic bone marrow transplantation

RADIATION

total-body irradiation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Thomas Manley, MD · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Eligibility

Max Age
1 Year
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547235 on ClinicalTrials.gov